Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Monthly Emicizumab Shows Value in Bleed Control

Publish date:: May 1, 2019

Key clinical point: For many patients with hemophilia A, with or without inhibitors, monthly treatment with emicizumab is enough to ensure a high level of bleed control.

Major finding: Twenty-three out of 41 patients (56.1%) reported no treated bleeds.

Study details: An ongoing, open-label phase 3 trial involving patients aged 12 years and older with severe congenital hemophilia A or hemophilia A with FVIII inhibitors who were receiving treatment with bypassing agents or FVIII concentrates.

Disclosures: F. Hoffman-La Roche and Chugai funded the study. The investigators reported financial relationships with the study sponsors and other companies.

Citation:

Pipe SW et al. Lancet Haem. 2019 Apr 16. doi: 10.1016/S2352-3026(19)30054-7.

This Week's Must Reads

Exercise PH poised for comeback as new definition takes hold,

Tramadol use for noncancer pain linked with increased hip fracture risk,

Gene therapy effective in hemophilia B patients with neutralizing antibodies,

Fast-tracked surgery for hip fracture does not reduce mortality,

Marijuana, drug use a mystery in IBD,

Must Reads in Hematology

Gene therapy effective in hemophilia B patients with neutralizing antibodies,

Fear drives activity changes in hemophilia patients,

Deferiprone noninferior to deferoxamine for iron overload in SCD, rare anemias,

Occult HCV infection is correlated to unfavorable genotypes in hemophilia patients,

Bariatric surgery candidates show high prevalence of thrombophilia,